Compare Abeona Therapeutics Inc (ABEO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs 22nd Century Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while 22nd Century Group Inc trades at $4.3 (market cap $1.48M). The key difference: Abeona Therapeutics Inc is far larger — about 252.2× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| ABEO | XXII | |
|---|---|---|
Market Cap | $373.32M | $1.48M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.04K |
52-Week Low | $4.17 | $3.90 |
Enterprise Value | $228.22M | -$6.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XXII trades at $4.28, up 6.73% in the last session, amid a bearish technical outlook. The company reported a net loss of $5.05M on $7.05M revenue in 2025, with negative profitability margins. Recent news highlights expansion of its VLN reduced-nicotine cigarettes into California and New York, aiming to capture market share. A 20:1 reverse stock split was executed on June 12, 2026, to adjust the share structure.
The outlook remains speculative with high execution risk; analyst consensus is 75% buy but fundamentals show deep losses. Key risks include sustained negative cash flow, regulatory hurdles for tobacco products, and reliance on financing. Upside depends on successful commercialization of VLN products and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
